Work

P3.12D.01 A Phase Ib Study of Osimertinib and Tegavivint as First-Line Therapy in Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Year: 2024

Type: article

Study design: Clinical Trial

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2024.09.623

Authors: R. Memmott, J. Gheeya, L. Wei, M. Phelps, W. Yang, D. Stenehjem, S. Horrigan, A. Duncan, D. Uribe, G. Amato, G. Otterson, J. Kaufman, A. Alahmadi, C. Presley, D. Owen, D. Carbone

Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, University of Minnesota, Iterion Therapeutics (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4403420340

FWCI: 0.255

Cites:

Cited by: 1

Related to: 10